The TROPION-Breast01 trial studied the antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) in previously treated HR+, HER2- breast cancer patients and showed improved progression-free survival to 7 months compared to 4.5 months with standard chemotherapy, with less high grade toxicity observed with Dato-DXd.
Related Keywords
Datopotamab Deruxtecan , , Emerging Therapies , Breast Cancer , Metastatic Breast Cancer , Mbc , Abc , Breast Cancer Treatments , Breast Cancer Therapies , Metastatic Breast Cancer Treatments ,
comparemela.com © 2020. All Rights Reserved.